Profil zamawiającego
Unidade Local de Saúde Santa Maria, E.P.E.
PT- Zamówienia
- 849
- Łączna wartość zamówień
- 948 073 972 €
- Kraje
- countries.PT
- Ostatnie zamówienie
- 14 lip 2026
- Wygasają w ciągu 12 miesięcy
- 0
Historia zamówień
| Data | Wykonawca | Tytuł | Kategoria | Wartość | Kraj | Wygasa | Źródło |
|---|---|---|---|---|---|---|---|
| 14.07.2026 | GILEAD SCIENCES,LDA | Portugal – Pharmaceutical products – 2023/0481 - SACITUZUMAB GOVITECANO [200 MG PÓ CONC SOL INJ FRS] | — | 164,2 tys. € | PT | — | Zobacz w TED ↗ |
| 14.07.2026 | SANOFI-PRODUTOS FARMACÊUTICOS,LDA | Portugal – Pharmaceutical products – 2025/1303 - DUPILUMAB [300 MG/ 2 ML SOL INJ CANETA] | — | 328,5 tys. € | PT | — | Zobacz w TED ↗ |
| 14.07.2026 | GILEAD SCIENCES,LDA | Portugal – Pharmaceutical products – 2023/0481 - SACITUZUMAB GOVITECANO [200 MG PÓ CONC SOL INJ FRS] | — | 684,2 tys. € | PT | — | Zobacz w TED ↗ |
| 14.07.2026 | Novo Nordisk Portugal, Lda | Portugal – Blood products – 261G000744 - Eptacog alfa (activado) 250 K.U.I. Pó so | — | 669,8 tys. € | PT | — | Zobacz w TED ↗ |
| 14.07.2026 | Boehringer Ingelheim Portugal, Lda | Portugal – Pharmaceutical products – 2025/1589 - NINTEDANIB [150MG CÁPS] | — | 18,6 tys. € | PT | — | Zobacz w TED ↗ |
| 14.07.2026 | SANOFI-PRODUTOS FARMACÊUTICOS,LDA | Portugal – Pharmaceutical products – 2025/1303 - DUPILUMAB [300 MG/ 2 ML SOL INJ CANETA] | — | 506,7 tys. € | PT | — | Zobacz w TED ↗ |
| 14.07.2026 | SANOFI-PRODUTOS FARMACÊUTICOS,LDA | Portugal – Pharmaceutical products – 2025/1303 - DUPILUMAB [300 MG/ 2 ML SOL INJ CANETA] | — | 1,6 mln € | PT | — | Zobacz w TED ↗ |
| 14.07.2026 | SANOFI-PRODUTOS FARMACÊUTICOS,LDA | Portugal – Pharmaceutical products – 2025/1303 - DUPILUMAB [300 MG/ 2 ML SOL INJ CANETA] | — | 328,5 tys. € | PT | — | Zobacz w TED ↗ |
| 14.07.2026 | Boehringer Ingelheim Portugal, Lda | Portugal – Pharmaceutical products – 2025/1589 - NINTEDANIB [150MG CÁPS] | — | 252,9 tys. € | PT | — | Zobacz w TED ↗ |
| 14.07.2026 | Boehringer Ingelheim Portugal, Lda | Portugal – Pharmaceutical products – 2025/1589 - NINTEDANIB [150MG CÁPS] | — | 3,8 tys. € | PT | — | Zobacz w TED ↗ |
| 14.07.2026 | GILEAD SCIENCES,LDA | Portugal – Pharmaceutical products – 2023/0481 - SACITUZUMAB GOVITECANO [200 MG PÓ CONC SOL INJ FRS] | — | 136,8 tys. € | PT | — | Zobacz w TED ↗ |
| 13.07.2026 | CICLUM FARMA UNIPESSOAL, LDA | Portugal – Immune sera and immunoglobulins – 261A000098 - C.Central Medicamentos 2026 - 2026/0312 (-BEVACIzumab ) | — | 71,1 tys. € | PT | — | Zobacz w TED ↗ |
| 13.07.2026 | Cencora 3PL Portugal | Portugal – Immune sera and immunoglobulins – 261A000098 - C.Central Medicamentos 2026 - 2026/0312 (-BEVACIzumab ) | — | 47,4 tys. € | PT | — | Zobacz w TED ↗ |
| 10.07.2026 | IMADIAGNOSIS - IMAG. DIAGNÓST., SA | Portugal – Medical imaging services – 269X000200 – “Prestação de serviços de realização de meios complementares de diagnóstico e terapêutica, na área de Imagiologia - Ecografias, a utentes da Unidade Local de Saúde de Santa Maria, E.P.E., para os meses de maio a dezembro de 2026 | — | 544,1 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | ROCHE FARMACÊUTICA QUÍMICA, LDA. | Portugal – Pharmaceutical products – 2023/0491 - ATEZOLIZUMAB [1200 MG/ 20 ML SOL INJ FRS] | — | 166,8 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | ABBVIE, LDA | Portugal – Pharmaceutical products – 2023/0491 - VENETOCLAX [100 MG CÁP/ COMP] | — | 1,7 mln € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | VIIVHIV HEALTHCARE, UNIPESSOAL, LDA | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR + ABACAVIR + LAMIVUDINA [50 MG + 600 MG + 300 MG CÁP/COMP] | — | 1,9 mln € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | Cencora 3PL Portugal | Portugal – Pharmaceutical products – 2026/0098 - ELOSULFASE ALFA [1 MG/ML 5 ML SOL INJ F/AMP] | — | 2,6 mln € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | DAIICHI SANKYO PORTUGAL , LDA | Portugal – Pharmaceutical products – 2025/1303 - TRASTUZUMAB DERUXTECANO [100 MG PÓ CONC SOL INJ FRS] | — | 1,3 mln € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | BAXTER MEDICO FARMACEUTICA, LDA | Portugal – Pharmaceutical products – 2026/0009 - FACTORES DE COAGULAÇÃO DO SANGUE - COLA P TECIDOS [10 ML] (ML) | — | 66,8 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | ROCHE FARMACÊUTICA QUÍMICA, LDA. | Portugal – Pharmaceutical products – 2023/0491 - ATEZOLIZUMAB [1200 MG/ 20 ML SOL INJ FRS] | — | 136,7 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | SANOFI-PRODUTOS FARMACÊUTICOS,LDA | Portugal – Pharmaceutical products – 2025/1303 - ISATUXIMAB [20 MG/ML 25 ML SOL INJ FRS] | — | 75,2 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | Montez & Melo, Lda - Residência Orquídea | Portugal – Residential health facilities services – 269G000444 - “Prestação de serviços de internamento e de cuidados de saúde a utentes da Unidade Local de Saúde de Santa Maria, E.P.E. – 2 camas de retaguarda de tipologia de unidade longa duração e manutenção, para o mês de abril de 2026 | — | 5,4 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | LAB. PFIZER, LDA | Portugal – Pharmaceutical products – 2024/0963 - VACINA POLISSACÁRIDA CONJUGADA CONTRA A DOENÇA PNEUMOCÓCICA DE 20 VALÊNCIAS (Pn20) [UDOSE] | — | 285,0 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | ABBVIE, LDA | Portugal – Pharmaceutical products – 2023/0491 - VENETOCLAX [100 MG CÁP/ COMP] | — | 345,2 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | ROCHE FARMACÊUTICA QUÍMICA, LDA. | Portugal – Pharmaceutical products – 2023/0491 - ATEZOLIZUMAB [1200 MG/ 20 ML SOL INJ FRS] | — | 697,0 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | DAIICHI SANKYO PORTUGAL , LDA | Portugal – Pharmaceutical products – 2025/1303 - TRASTUZUMAB DERUXTECANO [100 MG PÓ CONC SOL INJ FRS] | — | 363,0 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | BAXTER MEDICO FARMACEUTICA, LDA | Portugal – Pharmaceutical products – 2026/0009 - FACTORES DE COAGULAÇÃO DO SANGUE - COLA P TECIDOS [10 ML] (ML) | — | 49,5 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | SANOFI-PRODUTOS FARMACÊUTICOS,LDA | Portugal – Pharmaceutical products – 2025/1303 - ISATUXIMAB [20 MG/ML 25 ML SOL INJ FRS] | — | 290,9 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | BAXTER MEDICO FARMACEUTICA, LDA | Portugal – Pharmaceutical products – 2026/0009 - FACTORES DE COAGULAÇÃO DO SANGUE - COLA P TECIDOS [10 ML] (ML) | — | 245,4 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | DAIICHI SANKYO PORTUGAL , LDA | Portugal – Pharmaceutical products – 2025/1303 - TRASTUZUMAB DERUXTECANO [100 MG PÓ CONC SOL INJ FRS] | — | 345,6 tys. € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | VIIVHIV HEALTHCARE, UNIPESSOAL, LDA | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR + ABACAVIR + LAMIVUDINA [50 MG + 600 MG + 300 MG CÁP/COMP] | — | 373,0 tys. € | PT | — | Zobacz w TED ↗ |
| 02.07.2026 | Linde Saúde, Lda. | Portugal – Cleaning and sanitation services – 269G000215 - “Prestação de serviços de Telemonitorização domiciliária a utentes da ULSSM, E.P.E, com Doença Pulmonar Crónica e Insuficiência Cardíaca, para os meses de janeiro e fevereiro de 2026. | — | 25,5 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | NOVARTIS FARMA - PROD.FARM SA | Portugal – Pharmaceutical products – 2023/0491 - RIBOCICLIB [200 MG CÁP/ COMP] | — | 226,2 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | MERCK, S.A | Portugal – Pharmaceutical products – 2023/0491 - AVELUMAB [20 MG/ ML 10 ML FRS] | — | 217,4 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | ABBVIE, LDA | Portugal – Pharmaceutical products – 2025/1428- TOXINA BOTULÍNICA A [100 U ID IM F/AMP] | — | 319,7 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | VIIVHIV HEALTHCARE, UNIPESSOAL, LDA | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR [50 MG CÁP/COMP] | — | 434,3 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | NOVARTIS FARMA - PROD.FARM SA | Portugal – Pharmaceutical products – 2023/0491 - RIBOCICLIB [200 MG CÁP/ COMP] | — | 172,1 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | VIIVHIV HEALTHCARE, UNIPESSOAL, LDA | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR + RILPIVIRINA [50 MG + 25 MG CÁP/ COMP] | — | 166,9 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | MYLAN, LDA | Portugal – Pharmaceutical products – 2025/1303 - ENTECAVIR [0.5 MG CÁP/COMP] | — | 251,7 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | BIOGEN PORTUGAL- SOC.FARMAC., LDA | Portugal – Pharmaceutical products – 2023/0436 - NUSINERSEN [12 MG/5 ML SOL INJ FRS] | — | 380,6 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | VIIVHIV HEALTHCARE, UNIPESSOAL, LDA | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR + RILPIVIRINA [50 MG + 25 MG CÁP/ COMP] | — | 232,6 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | BRISTOL MYERS SQUIBB FARM.PORT, SA | Portugal – Pharmaceutical products – 2025/1303 - ENTECAVIR [0.5 MG CÁP/COMP] | — | 189,1 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | NOVARTIS FARMA - PROD.FARM SA | Portugal – Pharmaceutical products – 2023/0491 - RUXOLITINIB [5 MG CÁP/ COMP] | — | 235,1 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | ABBVIE, LDA | Portugal – Pharmaceutical products – 2025/1428- TOXINA BOTULÍNICA A [100 U ID IM F/AMP] | — | 63,9 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | NOVARTIS FARMA - PROD.FARM SA | Portugal – Pharmaceutical products – 2023/0491 - RUXOLITINIB [5 MG CÁP/ COMP] | — | 154,3 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | MERCK, S.A | Portugal – Pharmaceutical products – 2023/0491 - AVELUMAB [20 MG/ ML 10 ML FRS] | — | 165,9 tys. € | PT | — | Zobacz w TED ↗ |
| 09.06.2026 | NOVARTIS FARMA - PROD.FARM SA | Portugal – Pharmaceutical products – 2023/0491 - SECUCINUMAB [300 MG/2 ML SOL INJ CANETA/ SERINGA] | — | 461,8 tys. € | PT | — | Zobacz w TED ↗ |
| 09.06.2026 | OCTAPHARMA- PROD.FARMACEUTICOS, LDA | Portugal – Pharmaceutical products – 2025/1589 - IMUNOGLOBULINA HUMANA NORMAL, 165 MG/ML, SC (g) | — | 145,9 tys. € | PT | — | Zobacz w TED ↗ |
| 09.06.2026 | ROCHE FARMACÊUTICA QUÍMICA, LDA. | Portugal – Pharmaceutical products – 2023/0491 -PERTUZUMAB + TRASTUZUMAB [60 + 60 MG/ML SOL INJ FRS] | — | 230,9 tys. € | PT | — | Zobacz w TED ↗ |